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Abstract: A series of eight novel 5-substituted derivatives of benzimidazole 
was synthesized by condensation of the corresponding diamine with ethyl 4-[4- 
-(2-chlorophenyl)piperazin-1-yl]butanoate in refluxing 4 M hydrochloric acid. 
In vitro antibacterial activity against ten strains, namely Bacillus subtilis, Clos-
tridium sporogenes, Streptosporangium longisporum, Micrococcus flavus, Sar-
cina lutea, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, 
Salmonella enteritidis and Proteus vulgaris and antifungal activity against two 
fungal strains, namely Candida albicans and Saccharomyces cerevisiae, were 
evaluated. Of all the compounds screened for activity, 2-{3-[4-(2-chlorophe-
nyl)piperazin-1-yl]propyl}-5-iodo-1H-benzimidazole and 2-{3-[4-(2-chloro-
phenyl)piperazin-1-yl]propyl}-5-methyl-1H-benzimidazole were associated 
with higher antifungal activity than commercial drugs. 
Keywords: arylpiperazines; benzimidazoles; antibacterial activity; antifungal 
activity. 
INTRODUCTION 
One of the main objectives of organic and medicinal chemistry is the design, 
synthesis and production of molecules having value as human therapeutic 
agents.1–3 The synthesis of nitrogen-containing heterocyclic systems has been 
attracting interest over the past decade because of their utility in various appli-
cations.4–7 Substituted benzimidazoles and arylpiperazines derivatives have been 
one of the most extensively studied classes of heterocyclic compounds, receiving 
much attention from synthetic organic chemists because of their broad spectrum 
of biological properties, such as antiviral, anticancer, antibacterial, antifungal and 
many others.8–11 
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These results were an inspiration to synthesize compounds containing a sys-
tem that involves the combination of these pharmacophores in one molecular 
framework to give the title structure in order to screen their antimicrobial acti-
vities. Resent observations showed that the antimicrobial activities of 4-substi-
tuted piperazines varied significantly depending of the substituent group at the 4-
piperazine position, suggesting the necessity of an H-bond acceptor and/or donor 
group at the 4N-position.12 Prompted by these observations and in continuation 
the search for bioactive molecules, a series of novel 5-substituted benzimidazoles 
was designed and synthesized. The design emphasized the strategy of combining 
two chemically different but pharmacologically compatible molecules, benzimi-
dazole and arylpiperazine, with an alkyl chain that provides hydrophobic inter-
actions and the 2-chlorophenyl group in the piperazine part of the molecule that 
ensured H-bonding. The aim was to determine the influence of the substituent in 
the benzimidazole part of the molecule on the antimicrobial activities of the 
molecules.  
EXPERIMENTAL 
General 
The 1H-NMR and 13C-NMR spectra were recorded at 200 and 50 MHz, respectively, on 
a Gemini 2000 (Varian, Oxford). The spectra were recorded in deuterochloroform with 
tetramethylsilane as the internal standard; the chemical shifts (δ) are reported in parts per 
million (ppm). LC/MS was performed on a 6210 Time-of-Flight LC-MS system (Agilent 
Technologies, Germany). For data analysis, MassHunter Workstation Software was used. 
The infrared (IR) spectra were run on a Thermo Scientific spectrometer. For analytical 
thin-layer chromatography (TLC), POLYGRAM SIL G/UV254 plastic-backed thin-layer silica 
gel plates were used (Macherey-Nagel, Germany). Chromatographic purifications were per-
formed on Merck-60 silica gel columns (diameter 70 mm, h = 45 mm; the same for all 
compounds), 230–400 mesh ASTM, under medium pressure (dry column flash chromato-
graphy). All reagents and solvents used in this work were obtained from Alfa–Aesar and used 
without further purification. Solvents were routinely dried over anhydrous Na2SO4 prior to 
evaporation. 
Analytic and spectral data for compounds 3 and 20–27 are given in the Supplementary 
material to this paper. 
Chemistry 
Synthesis of ethyl 4-[4-(2-chlorophenyl)piperazin-1-yl]butanoate (3).  Suspension of 
1-(2-chlorophenyl)piperazine monohydrochloride (2) (25 g, 107.3 mmol), triethylamine 
(10.84 g, 107.3 mmol), K2CO3 (30 g, 214.6 mmol) and ethyl 4-bromobutanoate (1) (20.93 g, 
107.3 mmol) in 2-butanone (120 mL) was stirred for 24 h at 80 °C. After cooling, the mixture 
was poured into cold water and the organic layer was extracted with CH2Cl2 and concentrated 
in vacuo. The resulting ester was purified by silica gel column chromatography using a 
gradient of methanol (0–5 %, predicted by TLC) in dichloromethane. Yield: 22.6 g (68 %). 
General procedure for the reduction of 2-nitroaniline (4) and 4-substituted 2-nitroanilines 5–11 
Ra/Ni (0.4–0.5 g) was added in small portions to a stirred solution of 6.5 mmol of the 
required nitro compound (4–11) in 12 mL EtOH, 12 mL 1,2-dichloroethane and 2 mL (20 
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mmol) hydrazine hydrate at 30 °C. After completion of the Ra/Ni addition, the mixture was 
heated in a water bath (50 °C, 60 min) and filtered through celite. The filtrate was evaporated 
in vacuo and crude product used for further syntheses. 
General procedure for the synthesis of 1H-benzimidazoles 20–27 
Diamines 12–19 (5.56 mmol), ester 3 (4.2 g, 13.5 mmol) and 4 M HCl (28 mL) were 
heated at100 °C for 24 h. After cooling to ambient temperature, the reaction mixture was 
poured into ice-cold water and neutralized with a saturated solution of sodium hydroxide. The 
product was extracted with CH2Cl2 and concentrated in vacuo. The resulting 1H-benzimi-
dazoles were purified by silica gel column chromatography using a gradient of methanol (0–5 
%) in dichloromethane.  
Antimicrobial activity 
Sterile 96-well polystyrene microtiter plates with well capacities of 300 µL were used 
and 100 µL of fresh Mueller Hinton broth were added to each well of the plate. One hundred 
microliters of a stock solution (10 mg/mL) of the compound in DMSO were added to each 
well of the first column. Then, 100 µL of the solution were removed from the first column and 
mixed thoroughly with the broth in the corresponding wells of the second column. Sub-
sequently, a 100 µL aliquot was removed from each well in this column and mixed with 
contents of the corresponding well of the next column. This doubling dilution was performed 
in all rows across the plate. Two rows in each plate were used as controls. One row was used 
as a positive control and contained a broad-spectrum antibiotic, chloramphenicol, to determine 
the sensitivity of Gram-positive and Gram-negative bacterial species, and the antimycotics 
nystatin and fluconazole, to determine the sensitivity of the fungal species. The other row 
contained the solvent (DMSO) as a negative control. In each well of the plate, 10 µL of bac-
terial cultures (106 cells per mL) for antibacterial activity and 10 µL of fungi-cultures (105 
spores per mL) were inoculated. The microtitre plate was incubated at 37 °C for 24 h for 
bacteria or at 30 °C for 48 h for the fungi. Subsequently, the bacterial and fungi growth were 
measured. The MIC was determined as the lowest concentration that resulted in inhibition of 
bacterial and fungal growth. 
RESULTS AND DISCUSSION 
Synthesis of 5-substituted derivatives of benzimidazole, depicted in Scheme 
1, started with the preparation of ethyl 4-[4-(2-chlorophenyl)piperazin-1-yl]buta-
noate (3) from 1-(2-chlorophenyl)piperazine monohydrochloride (2) and ethyl 
4-bromobutanoate (1) in 2-butanone. 2-Nitroaniline (4) and 4-substituted 2-nitro-
anilines  5–11 were reduced by Ra-Ni/hydrazine to give the diamines 12–19, 
which were converted to the benzimidazoles 20–27 by condensation with the 
starting ester 3 in refluxing 4 M HCl. 
The micro-broth dilution assay was used to evaluate the antimicrobial effi-
cacy of all newly synthesized compounds against Gram-positive and Gram-nega-
tive bacteria and fungal cells. The results are presented in Tables I and II for the 
antibacterial and antimycotic activities, respectively.13 
The Gram-positive bacteria used were Bacillus subtilis (ATCC 6633), Clostri-
dium sporogenes (ATCC 19404), Streptosporangium longisporum (ATCC 25212), 
Micrococcus flavus (ATCC 10240), Sarcina lutea (ATCC 9341) and Staphylo-
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coccus aureus (ATCC 6538). The Gram-negative bacteria used were Escherichia 
coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 9027), Salmonella enter-
itidis (ATCC 13076) and Proteus vulgaris (ATCC 13315). The fungi tested were 
Candida albicans (ATCC 10231) and Saccharomyces cerevisiae (ATCC 9763). 
 
Scheme 1. Synthesis of 5-substituted derivatives of benzimidazole. Reagents: a) Et3N, K2CO3 
and  2-butanone; b) 1,2-dichloroethane, EtOH, NH2NH2 and Raney Ni; c) 4 M HCl, ester 3. 
TABLE I. Antibacterial activity (MIC / mg mL-1) of compounds 20–25 
Bacteria 
Compound 
20 21 22 23 24 25  Chloramphenicol 
B. subtilis  1.250 1.250  1.250  1.250  0.625  0.312  0.015 
0.250 
0.066 
0.031 
0.125 
0.015 
0.125 
0.250 
0.043 
0.043 
C. sporogenes  1.250 2.500 1.250 1.250 1.250 1.250 
S. longisporum  1.250 1.250  1.250 1.250 0.625  0.625 
M. flavus 1.250  2.500  1.250  1.250  0.625  0.625 
S. lutea 1.250  1.250  1.250  1.250  0.625  1.250 
S. aureus 1.250  2.500  2.500  0.625  0.312  0.312 
P. vulgaris  1.250 2.500 1.250  1.250 0.625  2.500 
P. aeruginosa  1.250 2.500 2.500  1.250 0.312  2.500 
S. enteritidis  1.250 2.500 2.500  1.250 1.250  1.250 
E. coli  1.250 –  –  0.312  0.625  0.312 
TABLE II. Antifungal activity (MIC / mg mL-1) of compounds 20–25 
Fungi 
Compound 
20 21 22 23 24 25  Nystatin Fluconazole
C. albicans  1.250 1.250  1.250  1.250  0.625  0.078  2.250 
1.250 
0.313 
S. cerevisiae  1.250 1.250  1.250  1.250  0.625  0.313 
Results revealed that, among all the synthesized and tested compounds, 
compounds  26 and 27  did not show antibacterial activity. The most potent 
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against the Gram-positive and Gram-negative bacteria were 2-{3-[4-(2-chloro-
phenyl)piperazin-1-yl]propyl}-5-iodo-1H-benzimidazole (24) and 2-{3-[4-(2-
chlorophenyl)piperazin-1-yl]propyl}-5-methyl-1H-benzimidazole (25). 
A comparison of activity data of all tested compounds and antifungal activity 
of nystatin and fluconazole indicated that all synthesized derivatives showed the 
same or better activity against C. albicans and S. cerevisiae than nystatin (except 
for 5-(trifluoromethyl) and 5-methoxy derivatives, 26 and 27, respectively). The 
5-methyl derivative 25 was four times more biologically active against C. albi-
cans than fluconazole. 
CONCLUSIONS 
The synthesis of a series of eight novel 2-{3-[4-(2-chlorophenyl)piperazin-1-
yl]propyl}-5-substituted-1H-benzimidazoles is presented, emphasizing the stra-
tegy of combining two chemically different but pharmacologically compatible 
heterocyclic molecules (benzimidazole and arylpiperazine) in one frame. The 
synthesized compounds were tested in vitro for their antibacterial and antifungal 
activities. The results indicate that, although the length of the aliphatic chain 
affects lipophilicity and 2-chlorophenyl group in the piperazine part of molecule 
provides for H-bonding (properties which are mandatory for antibacterial and 
antifungal activity), only the substituent in benzimidazole part of the molecule 
was crucial for the activity. Although the title compounds did not exhibit sig-
nificant antibacterial activity, all of them (except 26 and 27) exhibited the same 
or better antifungal activity than commercial nystatin and fluconazole. In some 
case of the fungi C. albicans, this activity was 4 times higher. More specifically, 
5-iodo 24 and 5-methyl 25 derivatives exhibited the best activities against both 
fungal species. 
SUPPLEMENTARY MATERIAL 
Analytic and spectral data for compounds 3 and 20–27 are available electronically from 
http:// //www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
СИНТЕЗА И БИОЛОШКО ИСПИТИВАЊЕ 5-СУПСТИТУИСАНИХ ДЕРИВАТА 
БЕНЗИМИДАЗОЛА 
ВЕСНА П. ВАСИЋ
1, JEЛЕНА З. ПЕЊИШЕВИЋ
2, ИРЕНА Т. НОВАКОВИЋ
2, ВЛАДИМИР В. ШУКАЛОВИЋ
2, ДЕАНА 
Б. АНДРИЋ
1 и СЛАЂАНА В. КОСТИЋ-РАЈАЧИЋ
2 
1Хемијски факултет, Универзитет у Београду, Студентски трг 12–16, Београд и 2ИХТМ – Центар 
за хемију, Универзитет у Београду, Његошева 12, Београд 
Синтетисана је серија од осам нових, 5-супституисаних бензимидазола, конденза-
цијом одговарајућег диамина са етил-4-[4-(2-хлорфенил)пиперазин-1-ил]-бутаноатом у 
4 М HCl, на температури рефлуктовања. Одређена је in vitro антибактеријска активност 
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на десет сојева, Bacillus subtilis, Clostridium sporogenes, Streptosporangium longisporum, Mic-
rococcus flavus, Sarcina lutea, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, 
Salmonella enteritidis и Proteus vulgaris, и антифунгална активност на два соја, Candida 
albicans  и  Saccharomyces cerevisiae.  Од  свих  новосинтетисаних  једињења  за 2-{3-[4-(2- 
-хлорфенил)пиперазин-1-ил]пропил}-5-јод-1Н-бензимидазол ( 24)  и 2-{3-[4-(2-хлорфе-
нил)пиперазин-1-ил]пропил}-5-метил-1Н-бензимидазол (25) се може истаћи да поседују 
бољу антифунгалну активност од комерцијалних лекова. 
(Примљено 18. априла, ревидирано 22. маја 2013) 
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